Skip to main content
. 2019 Mar 28;69(3):514–522. doi: 10.1093/cid/ciy913

Table 1.

Characteristics of Patients at Baseline (Entry)

Ledipasvir/Sofosbuvir for 8 Weeks
(N = 27)
Male sex, n (%) 27 (100)
Median age, y (IQR) 46 (38–50)
White, non-Hispanic, n (%) 11 (41)
Black, non-Hispanic, n (%) 5 (19)
Hispanic or Latino (regardless of race), n (%) 9 (33)
Asian or Pacific Islander, n (%) 2 (7)
Intravenous drug use, n (%)
 Current 1 (4%)
 Previous 4 (15%)
Reported history of STI, n (%) 11 (41)
IL28B CC favorable genotype, n (%) 16 (59)
HCV genotype, n (%)
 1a 23 (85)
 1b 3 (11)
 4 1 (4)
First HCV infection, n (%) 22 (81)
Median HCV RNA load, IU/mL (IQR) 1 490 000 (32 500-3 560 000)
Median HCV RNA load, log10 IU/mL (IQR) 6.17 (4.51–6.55)
HCV RNA load ≥ 6 million IU/mL, n (%) 6 (22)
Median time (days) from first laboratory evidence of acute infection (IQR) 116 (98–156)
Median CD4, cells/µL (IQR) 561 (441–698)
HIV-1 RNA <50 copies/mL, n (%) 27 (100)
Median ALT, mg/dL (IQR) 133 (47–393)
Median AST, mg/dL (IQR) 83 (35–224)
Median total bilirubin, mg/dL (IQR) 0.60 (0.50–1.20)
Median creatinine, mg/dL (IQR) 0.96 (0.88–1.15)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IL28B, interleukin 28B; IQR, interquartile range; STI, sexually-transmitted infection.